药学服务对慢性乙型肝炎患者药物治疗依从性的影响效果分析被引量：3

Effect of Pharmaceutical Care on Medication Compliance of Patients with Chronic Hepatitis B

下载PDF

导出

摘要目的探讨临床药师开展药学服务对口服抗病毒药物治疗的慢性乙型肝炎(chronic hepatitis B,CHB)患者用药依从性的影响。方法选取2015年9月至2016年8月(干预前组)与2016年9月至2017年8月(干预后组)来院就诊的CHB患者各150例,干预前组采用常规药物治疗,干预后组在常规治疗基础上持续性实施药学服务干预和为期48周的随访,比较两组患者干预前后药物治疗依从性及病情的转归,并对结果进行统计学分析。结果干预48周后患者对口服乙肝抗病毒药物的依从性(80.67%)明显优于干预前组(31.33%),两组比较差异有统计学意义(P<0.05),治疗48周时ALT复常率、HBV-DNA下降率以及HBsAg阴转率均显著优于干预前(P<0.05)。结论在CHB患者持续药物治疗时,临床药师加强对患者药学服务,提高了CHB患者用药依从性,从而保证了药物抗病毒治疗的效果。

作者范晓燕马佳商庆辉 Fan Xiaoyan;Ma Jia;Shang Qinghui

机构地区呼伦贝尔市人民医院临床药学部呼伦贝尔市人民医院检验科

出处《当代医学》 2019年第4期160-162,共3页 Contemporary Medicine

关键词乙型肝炎病毒慢性乙型肝炎药物依从性临床药师

分类号 R512.62 [医药卫生—内科学]

引文网络
相关文献

参考文献5

1慢性乙型肝炎防治指南（2015更新版）[J].中华肝脏病杂志,2015,23(12):888-905. 被引量：682
2窦晓光,丁洋.核苷（酸）类似物抗乙型肝炎病毒治疗的疗效预测[J].中华肝脏病杂志,2010,18(6):403-405. 被引量：1
3郑云英.PDCA循环护理对慢性乙型肝炎患者生存质量的干预效果分析[J].当代医学,2018,24(15):182-184. 被引量：14
4董国平.慢性乙型肝炎患者对乙肝知识认知情况及抗病毒治疗依从性的调查[J].中国公共卫生管理,2018,34(2):216-218. 被引量：13
5刘晓辉,余口,邓仰刚.干扰素联合阿德福韦酯对慢性乙肝患者HBV-DNA定量的影响[J].当代医学,2017,23(25):15-17. 被引量：2

二级参考文献57

1European Association For The Study Of The Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B.J Hepatol,2009,50:227-242.
2Zeuzem S,Buti M,Gane EJ,et al.Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis b (The GLOBE Study).Hepatology,2007,46 Suppl 1:681A.
3Andersson KL,Chung RT.Monitoring during and after antiviral therapy for hepatitis B.Hepatology,2009,49(5 Suppl):S166-173.
4Fontana RJ.Side effects of long-term oral antiviral therapy for hepatitis B.Hepatology,2009,49(5 Suppl):S185-195.
5Reddy KR,Rustgi V,Zeuzem S,et al.Week 24 is the optimal time point for predicting outcomes at 2 years with telbivudine.Global Antiviral J,2007,121 Suppl 2:13.
6Gane E,Lai CL,Min A,et al.Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study.J Hepatol,2007,46 Suppl 1:S187.
7Keeffe EB,Zeuzem S,Koff RS,et al.Report of an international workshop:Roadmap for management of patients receiving oral therapy for chronic hepatitis B.Clin Gastroenterol Hepatol,2007,5:890-897.
8Lee HC,Suh DJ,Ryu SH,et al.Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.Gut,2003,52:1779-1783.
9Chien R N,Yeh C T,Tsai S L,et al.Determinants for sustained HBeAg response to lamivudine therapy.Hepatology,2003,38:1267-1273.
10Yoon SK,Jang JW,Kim CW,et al.Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B:response and relapse rates,and factors related to durability of HBeAg seroconversion.Intervirology,2005,48:341-349.